The company is expected to expand beyond its cystic fibrosis business ... in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and ...

On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of ...

Reports Q3 revenue $2.77B, consensus $2.72B. “The third quarter marked another period of strong progress, with continued revenue growth ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering ... The firm focuses on development and commercializing therapies for the treatment ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

So when a business like Vertex Pharmaceuticals (NASDAQ ... just a few months away from being approved for sale, it's a big development. On that note, let's dive in and investigate how the bull ...